Breast Cancer 16-073 PALLAS

February 08, 2017

Sponsor: Memorial Sloan Kettering Cancer Center

Number: 16-073 PALLAS

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Who’s eligible: Patients must have Stage II or Stage III early invasive breast cancer, with ER+/PR+, HER2-. Multifocal, multicentric, or bilateral tumors must all meet pathologic criteria. May/ may not have received neo-adjuvant therapy, but must be after last dose of chemotherapy May/may not have received breast/axilla/post-mastectomy chest wall radiotherapy, but must be after last dose of radiotherapy with resolution to side effects. Patients must be randomized within 12 months of date of histological diagnosis. May have started adjuvant hormonal treatment, but must be randomized within 6 months of starting.

This study is for women age 18 and older.

Available at: Backus Hospital, MidState Medical Center, The Hospital of Central Connecticut, Hartford Hospital.

Cancer Clinical Research Office